NEWS. Sciety and Sciety Venture Partners have invested in Evidence, a healthtech company that has developed a digital platform for operational planning and management in healthcare. The funding will be used to scale up sales and marketing, expand the customer base, and further enhance the platform’s functionality. Among the new
INSIGHT. Looking back at pharmaceutical industry acquisition activity in 2024, a clear trend emerges: immunology and cancer dominated. These areas accounted for 70% of total transaction value, sending a strong signal about the industry’s growth potential. According to Biopharma Dive, 2024 saw a total of 39 acquisitions valued at over
INSIGHT. Healthcare systems worldwide are facing significant challenges. An ageing population, growing healthcare needs, and staff shortages are pressuring healthcare providers to find new, more accessible and cost-effective care models. One solution gaining increasing attention is virtual wards. The concept is based on allowing patients with lower care needs, such
PRESS RELEASE. Sciety and Sciety Venture Partners have invested EUR 3.9 million in PeptiSystems, a biotech company developing advanced manufacturing instruments for the rapidly growing peptide and oligonucleotide therapeutics market. The funds will be used to strengthen the company’s global expansion through increased production capacity, expanded sales, and further development
NEWS. 2024 has been a successful year for Sciety. We celebrated 10 years as a company, welcomed new key members to our team and saw several of our portfolio companies achieve significant advances that strengthen their market position. Throughout the year, we have continued to bridge scientific breakthroughs with tangible
INSIGHT. FDA’s latest drug approvals provide clear indications of future directions in drug development and point towards more personalised and groundbreaking treatments. Here are some of the key development areas we’re seeing right now: Breakthrough in gene editing The groundbreaking approval of Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics